unresectable stage III – IV melanoma research hub

Changes in the tumour microenvironment after intravenous or intradermal administration of anti-CTLA-4 in combination with anti-PD1 treatment in patients with melanoma

This study looks at how combining two anti-cancer drugs, YERVOY and an anti-PD1 treatment, affects the body's immune system in people with advanced melanoma. Researchers want to see if giving YERVOY directly into the skin works differently from giving it into a vein.